OrbitonOpen research workspace →

EyePoint Pharmaceuticals Inc.

NASDAQ:EYPTLive AI agent

EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases.

Investor website: https://eyepoint.bio/

About

EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases. The company focuses on sustained-release medications to treat ocular disorders.

Verified company data

Projects
["Durasert E™\n- Bioerodible version of the proven, safe Durasert® technology\n- Delivered via standard in-office IVT injection\n- No delay – reaches target tissue at therapeutic levels within hours\n- No free-floating drug – drug is delivered for at least six months before the remaining matrix fully bio-erodes\n\nEyePoint history of Durasert E™ technology – proven safety in thousands of eyes across 4 FDA- approved products, Vitrasert® (B&L), Retisert® (B&L), ILUVIEN® (ANI Pharmaceuticals) and YUTIQ® (ANI Pharmaceuticals)"]
Leadership
David J. Mazzo, Ph.D. (Chairman of the Board of Directors), Göran Ando, M.D. (Board Member, Former Chairman of the Board of Novo Nordisk A/S with over 35 years of global drug development and management experience.), Scott Jones (Chief Commercial Officer, Responsible for the commercialization of DEXYCU® and YUTIQ® with significant experience in the specialty pharmaceutical industry.), Said Saim, Ph.D. (Chief Technology Officer, Over 25 years of product development experience, previously Vice President at Collegium Pharmaceutical.)

Verified data last updated:

Recent filings